Navigation Links
Perrigo Company to Attend the 2011 Annual Meeting of the American College of Allergy, Asthma & Immunology

ALLEGAN, Mich., Oct. 28, 2011 /PRNewswire/ -- Perrigo Company today announced that it will attend the 2011 Annual Meeting of the American College of Allergy, Asthma & Immunology Conference (ACAAI) Nov. 3-8 at the Hynes Convention Center and the Sheraton Boston Hotel in Boston.

The ACAAI is a professional medical organization that promotes excellence in the practice of the medical subspecialty of allergy and immunology.  It is comprised of more than 5,000 allergists, immunologists and primary care physicians who care for allergy patients across the nation.  

Perrigo is among the top pharmaceutical companies in the world and is the largest manufacturer of "store-brand" over-the-counter (OTC) medicines for the nation's leading retailers, grocers, club stores and pharmacy chains. The company produces an extensive portfolio of store-brand allergy products that compare to leading national-brands, such as Loratadine tablets (Claritin®), Cetirizine HCl tablets (Zyrtec®), and the most recent non-sedating antihistamine to switch from prescription to over-the-counter, Fexofenadine HCl tablets (Allegra® Allergy).  Perrigo's FDA-approved store-brand portfolio offers consumers savings of at least 20 percent over national-brands.STORE-BRAND VERSUS NATIONAL-BRAND SAVINGS ON OTC ALLERGY PRODUCTSNational-Brand**

Store-Brand **

Savings** 52-week periodLoratadine tablets (Claritin®) 30ct



$153.79Cetirizine HCl tablets (Zyrtec®) 30ct



$87.36Fexofenadine HCl tablets  (Allegra®) 45ct



$68.94In addition to offering a number of products in store-brand, Perrigo also offers a full ORx® portfolio (OTC medicines-by-prescription) for patients whose public or private healthcare insurance covers OTC products when they are prescribed by a doctor.  Unlike OTCs today, ORx® products are still eligible for pre-tax flexible spending account dollars, which can result in significant additional savings.  

Although most prescribers are somewhat familiar with store-brands, perceptions and knowledge of how they are manufactured varies widely. Attendance at the 2011 ACAAI conference gives Perrigo the opportunity to interact with these influential clinicians in a more intimate setting and educate them on the value and quality store-brands offer patients.  

"Perrigo has been actively engaging the medical community and having a dialogue about store-brands as part of the overall healthcare picture," said Joseph Papa, president and CEO of Perrigo. "It was through these conversations that we recognized the particular importance of highlighting our commitment to manufacturing products of exceptional quality. If we expect physicians to feel confident recommending store-brands to their patients, we know we must communicate that every Perrigo drug is held to the same regulatory and quality standards as national-brand drugs.  And once they learn more about our company and our products, many do recommend store-brands."

** Prices and savings based on national averages of major retailers. Actual prices may vary. (SymphonyIRI Group, 52 weeks ending 6/5/11). Calculations are based on per tablet pricing x 1 daily single dose for 365 days.  

About Perrigo CompanyPerrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, active pharmaceutical ingredients (API) and pharmaceutical and medical diagnostic products.  The Company is the world's largest store-brand manufacturer of OTC pharmaceutical products and infant formulas. The Company's primary markets and locations of manufacturing and logistics operations are the United States, Israel, Mexico, the United Kingdom and Australia. Visit Perrigo on the Internet (

SOURCE Perrigo Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Perrigo Reports Record Quarterly Revenue and Adjusted Earnings and Raises Full Year Adjusted EPS Guidance
2. Perrigo Company Announces Quarterly Dividend
3. Perrigo Expands Infant Formula Distribution in China With Founder Group
4. Perrigo Company Will Release First Quarter Fiscal 2012 Results On October 27, 2011
5. Perrigo Company Confirms FDA Tentative Approval for Clobetasol Propionate Emulsion Foam
6. Perrigo to Host Analyst Day on October 5, 2011 at the TASE, Tel Aviv Stock Exchange in Tel Aviv, Israel
7. Perrigo to Host Analyst Day on September 27, 2011 at the NASDAQ MarketSite in Times Square
8. Perrigo Announces FDA Final Approval for Ketoconazole Foam, 2%
9. Perrigo Company Will Release Fourth Quarter Fiscal 2011 Results on August 16, 2011
10. Watson Enters into Agreement to Acquire Products Related to Perrigos Acquisition of Paddock Laboratories
11. Perrigo Closes Acquisition of Paddock Labs
Post Your Comments:
(Date:12/1/2015)... , Dec. 2, 2015  A combination of detailed ... the first time in the surgical planning for separation of ... annual meeting of the Radiological Society of North ... --> Conjoined twins, or twins whose bodies are connected, ... rates are low and separating them through surgery is extremely ...
(Date:12/1/2015)... , Dec. 1, 2015  A large study ... drug tamoxifen while taking an antidepressant found no increased ... today in The Journal of the National Cancer Institute. ... Tamoxifen is a commonly prescribed generic drug taken by ... developing a recurrence. Tamoxifen is recommended for five years, ...
(Date:12/1/2015)... Wash. and VANCOUVER , ... Committee (DMC) meeting, OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI ... is continuing based on the pre-planned interim futility analysis ... review, no new safety issues were identified by the ... all analyses and final results are expected in the ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... ... and hematology continuing medical education (CME), today announced that the first annual School ... New York. , “The prevention, detection and treatment of gastrointestinal cancers are undergoing ...
(Date:12/1/2015)... , ... December 01, 2015 , ... Growth in medical ... due to decreases in utilization of hospital and nonhospital care, according to a recent ... Medical Benchmarks for Louisiana, 16th Edition , found medical payments per claim with more ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... images have been lifted as IMAGE Information Systems launches MED-TAB™ -- the world’s ... America Annual Meeting from November 29 to December 4, 2015. , MED-TAB ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... Inc. (“Visage”), a wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME), has ... the Radiological Society of North America (RSNA) 2015 annual meeting through December 3 ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... clinical solutions for the care management and population health arenas, is pleased to ... clinical and cost containment services, has successfully implemented the ACUITY Complete Care™ Management ...
Breaking Medicine News(10 mins):